Cleveland BioLabs, U.S. Department of Health and Human Services other news

Cleveland BioLabs said HHS's Biomedical Advanced Research and Development Authority (BARDA) terminated negotiations related to the company's October 2012 proposal for further funding to develop entolimod ( CBLB502). According to Cleveland BioLabs, BARDA said "negotiations are always subject to availability of funds," but did not provide the company with any specific reasoning or details. The company plans to submit a request to FDA this quarter for a meeting to discuss a pre-Emergency Use Authorization pathway for entolimod. Cleveland BioLabs said it will make a decision on the future of the entolimod radiation program depending on the outcome of the meeting, which it expects to occur in 2Q14 (see BioCentury, Oct. 29, 2012). ...